Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
General Introduction | Nanhua Biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical technology company based on stem cell and regenerative medicine, driven by clinical cell transformation research and application, with a focus on cell storage, health management, beauty and anti-aging fields. Through the layout and efforts in the entire health industry chain, we aim to create a world-class biotechnology company. Nanhua Biology has formed a top scientist matrix with the Nobel Prize winner and Academician of the American Academy of Sciences Samenza as the strategic guidance, CAE Member Zhou Honghao as the chairman of the expert committee, CAS Member as the consultant, postdoctoral fellows of Harvard University as the backbone, and national 973/863 subject experts as the professional combination. The company has advanced cytology technology, built a world-class cell laminar flow culture room, created a scientific and efficient cell clinical application research system, and has rich experience in cell clinical research. As a state-owned listed company with the Hunan Provincial Government as the actual controller and Hunan Caixin Financial Holding Group as the largest shareholder, Nanhua Biotech takes "caring for the health of the people and benefiting the public" as its own responsibility, focusing on the biotechnology industry and promoting a new leap in human health. |
Headquarter | Changsha |
Establish Date | 10/18/1991 |
Listed Code | 000504.SZ |
Listed Date | 12/8/1992 |
Chairman | Yang Yun. |
CEO | You Changqiao. |
Website | www.landfar.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial